

Peace Harbor Medical Center Outpatient Infusion Service Request

Phone: (541) 902-6019 Fax: (541) 902-1649

Thank you for selecting our infusion services team to care for your patient. If you are not a PeaceHealth provider, all information listed below is required before we can process orders and schedule your patient for treatment. Part A- Patient scheduling and contact information: Patient Name (Last, First): _______Date of Birth: _____ Patient Contact Information and Phone Number (s): Ordering Provider Name (Print): Provider Clinic or Service Address: ______ Clinic or Service Phone Number: _____ Clinic or Service Fax Number: _____ Diagnosis (include ICD 10 codes): Medication and Service Requested- list J-Code/ CPT code if known: ______ Date Service is Requested to Begin: ______ Date Service is Expected to End: ___ Order will expire 1 year from date of provider signature unless "date service is expected to end" is earlier. <u>Part B- Insurance and Prior Authorization.</u> Any non-PeaceHealth provider must obtain prior authorization prior to service. Attach a copy of authorization documentation received from insurance payer when submitting orders. Insurance (Payer) Company: Prior Authorization Number and Conditions: Prior Authorization Expiration Date: _____ Insurance (Payer) Contact Phone Number: <u>Part C-</u> Elements needed to guide medication therapy are included with request for service: All orders and instruction (please use the PeaceHealth approved ordering form) are complete and include provider signature AND printed name at the bottom of each order page. Check the boxes of ALL orders you would like to activate. For blood products, PeaceHealth Blood and Transfusion Consent form is signed and dated by the provider and the patient. If information is located outside of PeaceHealth's electronic medical record system attach the following: A list of current medications reconciled by patient provider is available and includes a list of known allergies. Recent progress notes from ordering provider. A copy of relevant laboratory results and other appropriate supporting documentation. **IMPORTANT MESSAGE TO PROVIDERS:** To reduce delays in treatment and phone calls to your office you may participate in the PHMC formulary process by signing this document. A clinical pharmacist will adjust orders according to PHMC approved policies and procedures.

I agree to utilize PHMC policies & procedures that have been reviewed by the Pharmacy & Therapeutics Committee and authorized by the Medical Executive Committee of PHMC. This agreement will be issued for the duration of active orders contained within this treatment plan.

PROVIDER SIGNATURE: ______ DATE: _____ TIME:_____

FAX completed service request and completed orders to: PHMC OP Infusion and Nursing Services 541-902-1649



Progress & Orders



Ocrelizumab (Ocrevus) Outpatient Infusion Therapy Plan

All Pre-Selected Boxed Orders Are Initiated by Default Unless Crossed Out by Practitioner. All Boxed Orders Require Practitioner Check to be Initiated.

Heading	Content	
For Admission to	Provider Instruction – Please review information below and address requirements for admission to	
Service	service:	
	1. Provider has screened patient for active hepatitis B virus infection, latent hepatitis and tuberculosis infections in high-risk populations, malignancy, and history of chronic infections prior to initiation of Ocrevus. Ocrevus is contraindicated in patients with an active hepatitis B infection. Hepatitis B screening is required before first dose. Please order and evaluate required hepatitis B screening labs (hepatitis B surface antigen HBsAg and hepatitis B core antibody HBcAb) outside of this therapy plan prior to ordering Ocrevus.	
	Date of screening (required for service):	
	 Provider has verified that patient is up to date with all immunizations prior to initiation of Ocrevus. Live vaccines must be given at least 4 weeks prior to initiation of Ocrevus, and non-live vaccines must be given at least 2 weeks prior to initiation of Ocrevus. Instruct patients that if they are pregnant or plan to become pregnant while taking Ocrevus, they should inform their healthcare provider. Review the FDA approved medication guide for ocrelizumab (Ocrevus) with the patient and provide patient with a paper copy. 	
Labs	☐ CBC with automated differential once prior to beginning treatment and every months	
	☐ Comprehensive metabolic panel once prior to beginning treatment and every months	
	□ Other:	
Pre-Medications		
Pre-iviedications		
	□ Acetaminophen (Tylenol) 650 mg PO once 30 minutes prior to infusion	
	☐ DiphenhydrAMINE (Benadryl) 25 mg PO once 30 minutes prior to infusion	
Supportive Care	☑ Ocrelizumab (Ocrevus) IV infusion	
	Select Regimen:	
	☐ Initiation: 300 mg at zero (0) and 2 weeks followed by 600 mg maintenance infusion every 6 months	
	☐ Maintenance: 600 mg every 6 months	
	Additional order instruction:	
	☑ Administer through a dedicated IV line using a 0.2 or 0.22 micron in-line filter. For 300 mg doses	
	begin infusion at 30 ml/hour and increase by 30 ml/hour every 30 minutes to a maximum rate of	
	180 ml/hour. For 600 mg doses begin infusion at 40 ml/hour and increase by 40 ml/hour every 30	
	minutes to a maximum rate of 200 ml/hour.	
Nursing Orders	Ocrevus is contraindicated in patients with an active hepatitis B infection. On initial visit, verify that	
0	hepatitis B screening is complete.	
	 ✓ Hold Ocrevus infusion and notify provider for signs and symptoms of infection. 	
	 ✓ Vital signs to be done at baseline, as needed during and after infusion, and prior to discharge. 	
	 ✓ With signs to be done at baseline, as needed during and direct imasion, and prior to discharge. ✓ Observe patients for infusion reactions during and for at least one hour after completion of 	
	infusion. For mild to moderate infusion reactions reduce infusion to one-half of the rate at which	
	the reaction occurred and maintain reduced rate for at least 30 minutes. If the reduced rate is	
	tolerated, increase rate every 30 minutes by 30 ml/hour to a maximum rate of 180 ml/hour (300	
	mg dose) or 40 ml/hour to a maximum rate of 200 ml/hour (600 mg dose). For severe infusion	
	reactions immediately interrupt infusion and notify provider. Administer appropriate supportive	
	management as needed. After symptoms have resolved, restart infusion beginning at a rate one-	

Practitioner Signature:	Date of	f Order:	Гіте:
--------------------------------	---------	----------	-------

Final page of orders must include signature of the ordering practitioner, date, and time.

Date of Revision: 8/24/2023 Page 2 of 4



Progress & Orders



Ocrelizumab (Ocrevus) Outpatient Infusion Therapy Plan

All Pre-Selected Boxed Orders Are Initiated by Default Unless Crossed Out by Practitioner. All Boxed Orders Require Practitioner Check to be Initiated.

Heading	Content		
	half of the rate at the onset of reaction. If reduced rate is tolerated, increase the rate as above. For		
	life threatening infusion reaction immediately stop infusion, notify provider, and administer		
	appropriate supportive care. Permanently discontinue.		
Nursing IV Access	Select the most appropriate option below:		
and Maintenance	☐ Insert PERIPHERAL IV as needed and flush (unless provider selects option for a central line).		
	oxtimes Sodium chloride 0.9% (NS) flush 10 mL IV once as needed for line care.		
	☐ Access and use NON-PICC Central Line/CVAD		
	☐ Initiate Central Line (non-PICC) maintenance protocol.		
	☑ Sodium chloride 0.9% (NS) flush 10 mL IV as needed for line care, before and after medication		
	administration, at discharge, and at de-access (sterile NS for Port-a-Cath access)		
	☑ Sodium chloride 0.9% (NS) flush 20 mL IV as needed for line care post lab draw.		
	☐ Heparin, porcine (PF) 100 unit/mL flush 5 mL IV as needed for line care, for de-access.		
	☐ Alteplase (Cathflo) injection 2 mg intra-catheter as needed for occluded central line catheters-		
	For clearing central line catheter. Add 2.2 mL sterile water for injection to vial; let the vial stand		
	undisturbed to allow large bubbles to dissipate. Mix by gently swirling until completely		
	dissolved (complete dissolution should occur within 3 minutes); do not shake. Final		
	concentration: 1mg/mL. Retain in catheter for 30 minutes to 2 hours; may instill a second dose		
	if occluded.		
	☐ Access and use PICC Central Line/CVAD		
	☑ Initiate PICC maintenance protocol.		
	medication administration.		
	☑ Sodium chloride 0.9% (NS) flush 20 mL IV as needed for line care post lab draw		
	☐ Alteplase (Cathflo) injection 2 mg intra-catheter as needed for occluded central line catheters-		
	For clearing central line catheter. Add 2.2 mL sterile water for injection to vial; let the vial stand		
	undisturbed to allow large bubbles to dissipate. Mix by gently swirling until completely		
	dissolved (complete dissolution should occur within 3 minutes); do not shake. Final		
	concentration: 1mg/mL. Retain in catheter for 30 minutes to 2 hours; may instill a second dose		
	if occluded.		
As Needed	Standard As Needed Medications:		
Medications	Sodium chloride 0.9% (NS) flush 10 mL IV as needed for line care		
	Sodium chloride 0.9% 500 mL continuous infusion at 25 mL/hour IV as needed for therapy		
	administration (i.e., blood products, chemotherapy, potassium administration).		
Emergency	If patient has symptoms of anaphylaxis (wheezing, dyspnea, hypotension, angioedema, chest pain,		
Medications	or tongue swelling), discontinue infusion and initiate standard emergency response procedures.		
	Standard Emergency Medications:		
	☑ DiphenhydrAMINE (Benadryl) injection 25-50 mg IV once as needed for mild to moderate drug		
	reactions (flushing, dizziness, headache, diaphoresis, fever, palpitations, chest discomfort, blood		
	pressure changes (>/= 20 points in SBP), nausea, urticaria, chills, pruritic).		

Practitioner Signature:	Date of Order:	Time:
-------------------------	----------------	-------

Final page of orders must include signature of the ordering practitioner, date, and time.

Date of Revision: 8/24/2023 Page **3** of **4**



Progress & Orders



Ocrelizumab (Ocrevus) Outpatient Infusion Therapy Plan

All Pre-Selected Boxed Orders Are Initiated by Default Unless Crossed Out by Practitioner. All Boxed Orders Require Practitioner Check to be Initiated.

Heading	Content		
	Administer 50 mg IV if patient has NOT had diphenhydramine within 2 hours of reaction		
	 Administer 25 mg IV if patient has had diphenhydramine within 2 hours of reaction, if 		
	reaction doesn't resolve in 3 minutes may repeat 25 mg IV dose for a total of 50 mg and		
	contact provider.		
	☑ Albuterol 90 mcg/actuation inhaler 2 puffs once as needed for wheezing, shortness of breath		
	associated with infusion reaction and contact provider. Administer with spacer if available.		
	☑ MethylPREDNISolone (Solu-Medrol) injection 125 mg IV once as needed for shortness of breath		
	for continued symptoms of mild to moderate drug reactions (flushing, dizziness, headache,		
	diaphoresis, fever, palpitations, chest discomfort, blood pressure changes (>/= 20 points in SBP),		
	nausea, urticaria, chills, pruritic) that worsen or persist 5 minutes after administration of		
	diphenhydramine (Benadryl) and contact provider.		
	☑ EPINEPHrine (Adrenalin) injection 0.5 mg IM once as needed for severe drug reaction (flushing,		
	dizziness, headache, diaphoresis, fever, palpitations, chest discomfort plus blood pressure		
	changes (>/= 40 points in SBP), shortness of breath with wheezing and 02 Sat < 90% and contact		
	provider.		
Referral			
PHMC Outpatient	PROVIDER – PLEASE SIGN, DATE AND TIME ORDERS AND RETURN TO:		
Infusion Contact Information	PeaceHealth Peace Harbor Medical Center Outpatient Infusion Services Department 400 Ninth Street Florence, OR 97439 Contact Phone: 541-902-6019 and FAX 541-902-1649		
Authorization by	Person giving verbal or telephone order:		
Verbal or	Person receiving verbal or telephone order:		
Telephone Order	☐ Check to indicate verbal or telephone orders have been read back to confirm accuracy		

Practitioner Signature:	Date of Order:	Time:

Final page of orders must include signature of the ordering practitioner, date, and time.